Ruxolitinib

General description This substance is a primary reference substance with assigned absolute purity (considering chromatographic purity, water, residual solvents, and inorganic impurities). The exact value can be found on the certificate.

A natural flavonol glycoside with iron chelating and antioxidant properties demonstrates anti-inflammatory, anti-cancer, anti-fibrosis effects as well as hepato- and neuroprotective actions in animal models.

A natural flavonol glycoside with iron chelating and antioxidant properties demonstrates anti-inflammatory, anti-cancer, anti-fibrosis effects as well as hepato- and neuroprotective actions in animal models.

General description Rutin hydrate has radioprotective and antiplatelet activity. Rutin reduces hepatic and blood cholesterol levels.

MF: C27H30O16 MF: 610.52 CAS: 153-18-4 Purity: =99% by HPLC

Ruxolitinib

Ruxolitinib

INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, &gt:130-fold selectivity for JAK1/2 versus JAK3.An inhibitor of JAK1, JAK2, and JAK3.

INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, &gt:130-fold selectivity for JAK1/2 versus JAK3.An inhibitor of JAK1, JAK2, and JAK3.

INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, &gt:130-fold selectivity for JAK1/2 versus JAK3.An inhibitor of JAK1, JAK2, and JAK3.

INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, &gt:130-fold selectivity for JAK1/2 versus JAK3.An inhibitor of JAK1, JAK2, and JAK3.

INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, &gt:130-fold selectivity for JAK1/2 versus JAK3.An inhibitor of JAK1, JAK2, and JAK3.